Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378638 | 1.00 | BACE1 (0.35) | BACE1CTSDBACE2CYP19A1 | |
| SCHEMBL7541520 | 0.83 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL18180617 | 0.79 | BACE1 (0.43) | BACE1CTSDBACE2 | |
| SCHEMBL7555120 | 0.79 | RIPK1 (0.38) | — | |
| SCHEMBL20378647 | 0.79 | BACE1 (0.43) | BACE1CTSDBACE2 | |
| SCHEMBL20378585 | 0.77 | BACE1 (0.45) | BACE1CTSDBACE2CYP19A1 | |
| SCHEMBL18180670 | 0.77 | BACE1 (0.45) | BACE1CTSDBACE2CYP19A1 | |
| SCHEMBL30105911 | 0.77 | BACE1 (0.45) | BACE1CTSDBACE2CYP19A1 | |
| SCHEMBL7547230 | 0.77 | CYP2D6 (0.42) | CYP19A1 | |
| SCHEMBL18173748 | 0.77 | BACE1 (0.43) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | claimed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | claimed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | claimed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 182/4885BACE2 2/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885CTSD 176/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.